CD44 expression, a potential CSC marker, as determined in human BC CSC (phenotype CD44+/CD24-/low), was detected in scattered cells (score 1) in the 31% of the cases, or in limited tumor regions (score 2) in 15%, while 54% of tumors were negative. This evidence concerns the gene CD24 and breast cancer.